Thursday May 10 Educational Day Kinnear Centre, 2 nd Floor, Room KC201/203

Transcription

1 Thursday May 10 Educational Day Kinnear Centre, 2 nd Floor, Room KC201/ On Site Check-in and Registration 2 nd Floor Foyer 1300 Welcoming Remarks Drs David Eisenstat & Jay Easaw SESSION ONE Brain Metastases Moderator: Dr David Eisenstat Genomic Evolution of Brain Metastases: Implications for Precision Medicine Dr Priscilla Brastianos University of Alberta CRINA Lectureship Objectives: 1. To understand genetic heterogeneity in brain metastases; 2. To understand the key molecular changes in brain metastases when compared to primary tumors; 3. To be aware of promising therapeutic targets in brain metastases Toxicity of Therapeutic Radiation on the CNS and its Treatment Dr Victor Levin Objectives: 1. To understand the stages of radiation damage to the CNS; 2. To appreciate some of the imaging characteristics of the different stages of radiation damage to the CNS; 3. Understand the basis for bevacizumab (Avastin) treatment of radiation effect on the CNS BREAK KC Foyer SESSION TWO Glioma Moderator: Dr Jay Easaw Classification of Glioma Using Molecular Markers and Genomics Dr Jeffrey Joseph Objectives: 1. To understand the rationale for using molecular information in the classification of brain tumours; 2. To understand key molecular changes useful in the classification of different types of gliomas; 3. To be able to describe the WHO classification of diffuse gliomas utilizing molecular information, including oligodendroglioma, diffuse astrocytoma, and glioblastoma Management Elderly Patients with GBM Dr Norm Laperriere Objectives: The audience will: 1. Understand the latest data from randomized studies on management of elderly patients with glioblastoma. 2. Understand the impact of MGMT methylation on outcomes and choices for management and 3. be aware of the nuances of incorporation major clinical prognostic factors into the management of an individual patient Future of Clinical Trial Design Dr Wolfgang Wick Peters Lectureship in Brain Tumour Research Objectives: 1. to appreciate new concepts of precision medicine; 2. To understand mechanisms of patients selection and stratification; 3. To learn about the present stage of immunotherapy. Session Discussion (20 min) Business Meetings Room KC201/ CBTC Annual General Meeting (members only) CNO Society Planning Meeting (open to all) WELCOME RECEPTION + POSTER SESSION Rooms KC101 & 103

2 Friday May 11 Scientific Day Kinnear Centre, 2 nd Floor, Room KC201/ BREAKFAST Buffet Vistas Dining Room, Sally Borden Building Welcome and Opening Remarks Drs David Eisenstat & Jay Easaw SESSION THREE Basic Research Moderator: Dr David Eisenstat Full Circle: Bench to Bedside to Bench Dr Greg Cairncross Michael Rossman Brain Tumour Lectureship Objectives: 1. To describe the drug discovery approach used by the TFRI GBM team; 2. To describe the challenges faced in launching investigator initiated GBM trials; 3. To describe the types of drugs that looking most promising for GBM; 4. To discuss three potential roles for PARP-1 inhibitors in glioma therapy SESSION FOUR Biology of Brain Tumors Moderator: Dr David Eisenstat Brain Tumor Initiating Cells: Current Understanding and Application to Clinical Care Dr John Kelly Objectives: To define and characterize brain tumor initiating cells; 2. To understand how brain tumor initiating cells contribute to treatment resistance; 3. To understand cancer stem cell targeting strategies and applications to clinical care Progress in the Genomic Classification and Treatment of Meningioma Dr Priscilla Brastianos Objectives: 1. To understand the recent advances in our understanding of the genetics of meningiomas; 2. To be able to describe molecular classification of meningiomas; 3. To learn about promising therapeutic targets in meningiomas. Session Discussion (10 min) SESSION FIVE Glioblastoma Moderator: Dr Wolfgang Wick Focused Ultrasound Dr Kullervo Hynynen Objectives: 1. To understand how ultrasound can be used for brain tumour treatments; 2. To describe current clinical trials using ultrasound for brain tumor treatments; 3. To understand the future potential of ultrasound for brain tumour treatments Novel Therapeutics: Surgery with a Laser (NeuroAblate) Dr Brian Toyota Objectives: 1. To understand the biologic effect of laser ablation; 2. To understand the major risk of laser ablation; 3. To know the role of innovation in cancer care Radiogenomics: Understanding the Imaging Correlates of Adult GBM Genotypes Dr James Scott Objectives: 1. To learn about the topic of Radiogenomics; 2. To better understand how imaging phenotypes can help predict glioma genotype BREAK KC Foyer SESSION SIX GBM Oral Abstract Presentations Moderator: Dr Jay Easaw T Walbert Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC P Zhu Timing of Adjuvant Treatments on Glioblastoma Survival: A Retrospective Cohort Analysis Based on the National Cancer Database S Mansouri Alterations in the epigenetic profile of glioblastoma tumors within hypoxic tumor regions Session

3 Lunch service KC Foyer LUNCH SYMPOSIUM (all registrants welcome) Room KC 201/ SESSION SEVEN Pediatrics NeuroOncology Moderator: Dr David Eisenstat Advances in Diagnosis and Management of Pediatric Low Grade Glioma Dr Lucie Lafay-Cousin Objectives: 1. To explore our current understanding of the current molecular landscape of pediatric low grade glioma; 2. To introduce the therapeutic implications of these new molecular characterization Rare Brain Tumours of Childhood: Informing Treatment Paradigms Dr Annie Huang Objectives: 1. To develop understanding of clinical spectrum and presentation of malignant baby brain tumours; 2. To gain knowledge regarding specific challenges of treating young children with malignant brain tumours; 3. To gain knowledge of how new science and re-purposed clinical tools are making baby brain tumours a game changer Pediatric Oral Abstract Presentations Moderator: Dr David Eisenstat S Ryall *BTFC Award The genetic landscape of pediatric low-grade gliomas: incidence, prognosis and response to therapy: A SickKids plgg Task Force update L Liang *BTFC Award CD271/p75NTR is a novel diagnostic marker, prognostic indicator and therapeutic target for SHH medulloblastoma G Michaiel Intracranial growing teratoma syndrome (IGTS): An international retrospective study D Bakhshinyan *BTFC Award Genes preserving stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse Young Investigator Awards & Presentations Moderator: Dr David Eisenstat Basic/Translational VG LeBlanc Exploring cellular subpopulations in glioblastoma and matched organoids using single-cell RNA-seq Clinical/Translational F Nassiri Metabolic profiling of gliomas reveals distinct subgroups of tumors independent of IDH mutation status Discussion (15 min) SESSION EIGHT Glioma Oral Abstract Presentations Moderator: Dr James Perry D Yusuf *CRINA Award Identifying and prognosticating malignant brain tumors non-invasively using unique metabolomic signatures derived from patient serum and urine samples Y Mamatjan Integration of multiple platforms to discover idh-mutant glioma subtypes A Golebiewska Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor progression in vivo, upon bevacizumabinduced hypoxia BREAK KC Foyer + POSTER SESSION Room KC SESSION NINE Top Scoring Abstracts Moderator: Dr John Kelly D Wong Unraveling Molecular Drivers of Brain Cancers at the Clinical Setting C Poon Microglia and macrophages display heterogeneous phenotypes in IDH-mutant and -wildtype glioblastomas BV Sajesh Peroxiredoxin1 is a therapeutic target in group-3 medulloblastoma Shuttle buses depart for Mountview BBQ 107 Eagle Crescent

4 CNO2018 Social Event Mountview BBQ Dress Code: Country Chic After-dinner guest speaker: Dr Rob Rutledge Working with your wise and compassionate brain: The neuroscience and daily practice of resilience Saturday May 12 Selected Topics in Neuro-Oncology Kinnear Centre, 2 nd Floor, Room KC201/ BREAKFAST Buffet Vistas Dining Room, Sally Borden Building Is There a Best Second Line Therapy for GBM Dr Jay Easaw Objectives: 1. To understand survival statistics for patients who experience recurrent GBM; 2. To list treatment options for second line therapy and impact on overall survival; 3. To increase awareness of potential new therapeutic options now being assessed in clinical trial Optimal Management of Brain Mets Dr Arjun Sahgal BTFC Rolando Del Maestro Lectureship Objectives: 1. To understand the implication of SRS for patients with brain metastases; 2. To appreciate the evidence for SRS and more than 5 metastases; 3. To understand the effects of whole brain radiation on cognition Eflornithine Treatment of Gliomas and the Path to the STELLAR Study Dr Victor Levin Objectives: 1. To understand mechanisms of eflornithine antitumor activity; 2. To appreciate the laboratory and clinical history that preceded the current STELLAR study; 3. To appreciate the interplay between PFS and OS for primary CNS tumor gliomas SESSION TEN The Great DEBATE Moderator: Dr Wolfgang Wick PCV Dr Marshall Pitz vs Temozolomide Dr David Macdonald Discussion (10 min) BREAK KC Foyer + POSTER SESSION Room KC Development of CBTRUS and Implications for Development of a Canadian Brain Cancer Registry Dr Faith Davis Panel Discussion: Dr Yan Yuan & Ms Angela Eckstrand, MSc Candidate Objectives: To understand the background and progress on development of a Canadian Brain Tumour Registry; 2. To discuss what we have learned so far; 3. To obtain a consensus on definition for reporting primary brain tumours in Canada. Discussion (10 min) Selected CNO2018 Abstracts Moderator: Dr Marshall Pitz M Nevi (D Eisenstat presenting) Could Dlx2 regulation of neural progenitor cell fate contribute to differentiation of diffuse intrinsic pontine glioma (DIPG)? EV Walker Malignant primary brain and other central nervous system tumours diagnosed in the Canadian population from 2009 to S Suppiah Unique Immune Microenvironment in NF2-Fusion Positive Radiation Induced Meningiomas Discussion (15 min) Clinical Cases Co-Moderators: Drs Joseph Megyesi & David Macdonald 1300 ADJOURNMENT Drs David Eisenstat & Jay Easaw *BTFC Award = Brain Tumour Foundation of Canada Travel Award Recipient *CRINA Award = Cancer Research Institute of Northern Alberta Travel Award Recipient

5 FACULTY & PARTICIPANTS PRISCILLA K. BRASTIANOS, MD Director, Central Nervous System Metastasis Program Massachusetts General Hospital Harvard Medical School, Boston, MA GREG CAIRNCROSS, MD Professor, Department of Clinical Neurosciences University of Calgary Director, Charbonneau Cancer Institute FAITH DAVIS, PhD MPH MSc Professor and Vice-Dean School of Public Health, University of Alberta Edmonton, AB JAY EASAW, MD Associate Professor, University of Alberta Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB DAVID EISENSTAT, MD MA FRCPC Chair, Department of Oncology, University of Alberta Muriel & Ada Hole Kids with Cancer Society Chair in Pediatric Oncology Professor, Departments of Oncology, Medical Genetics and Pediatrics Edmonton, AB ANNIE HUANG, MD PhD FRCPC Staff Oncologist, Paediatric Brain Tumour Program Haematology/Oncology Hospital for Sick Children, Toronto ON KULLERVO HYNYNEN, MSc PhD Senior Scientist, Odette Cancer Research Program Sunnybrook Research Institute, Toronto ON JEFF JOSEPH, MD PhD Section Head, Neuropathology, University of Calgary and Calgary Laboratory Services Donald Burns and Louise Berlin Professor in Dementia Research Professor, Department of Pathology JOHN T. KELLY, MD PhD FRCSC Assistant Professor of Neurosurgery, University of Calgary Surgical Neuro-Oncology Program & Radiosurgery Centre of Alberta

6 LUCIE LAFAY-COUSIN, MD MSc Associate Professor, Departments of Oncology and Pediatrics University of Calgary, Faculty of Medicine Pediatric Oncologist, Alberta Children's Hospital NORMAND LAPERRIERE, MD FRCPC FRANZCR(Hon) Professor, Department of Radiation Oncology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto ON VICTOR A. LEVIN, MD Emeritus Professor, Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center Houston, TX DAVID MACDONALD, MD FRCPC Associate Professor, Department of Oncology and Dept of Clinical Neurological Sciences, University of Western Ontario, London, ON JOSEPH MEGYESI, MD Associate Professor of Neurosurgery, Western University Director of Research, Division of Neurosurgery, London Health Sciences Centre, London ON JAMES R PERRY, MD FRCPC Professor of Medicine, University of Toronto Sunnybrook Health Science Centre Tony Crolla Chair of Brain Tumour Research Toronto, ON MARSHALL PITZ, MD FRCPC Associate Professor of Medicine, Rady Faculty of Health Sciences University of Manitoba Medical Oncologist, Chief Medical Information Officer CancerCare Manitoba Head, Clinical Research, Research Institute in Oncology and Hematology, Winnipeg, MA ROB RUTLEDGE, MD FRCPC Associate Professor, Dalhousie University Radiation Oncologist, Nova Scotia Cancer Center Halifax, NS ARJUN SAHGAL, BSc MD FRCPC Professor of Radiation Oncology and Surgery, University of Toronto Deputy Chief, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre

7 Toronto, ON JAMES N. SCOTT, MD MSc FRCPC Departments of Diagnostic Imaging & Clinical Neurosciences Cumming School of Medicine, University of Calgary BRIAN D. TOYOTA, MD CM FRCSC Assistant Professor, University of British Columbia Chair, Division of Neurosurgery, Vancouver General Hospital Provincial Chair of Neuro-Oncology, BC Cancer Agency, Vancouver BC WOLFGANG WICK, MD Full Professor of Neurooncology, Chairman, Department of Neurooncology, University of Heidelberg Head Clinical Cooperation Unit Neurooncology, German Cancer Research Center CNO 2018 Scientific Program Committee: Dr Jay Easaw, Edmonton, Co-chair Dr David Eisenstat, Edmonton, Co-chair Dr Sidney Croul, Halifax Dr Spencer Gibson, Winnipeg Dr Roseline Godbout, Edmonton Dr Joseph Megyesi, London Dr Samir Patel, Edmonton Dr James Perry, Toronto Dr Marshall Pitz, Winnipeg Dr MI Vanan, Winnipeg